Scarica l'app Stockscreener
19.12
2.99%
-0.59
Dopo l'orario di chiusura:
19.12
Precedente Chiudi:
$19.71
Aprire:
$19.76
Volume 24 ore:
1.67M
Relative Volume:
0.90
Capitalizzazione di mercato:
$3.29B
Reddito:
$1.10B
Utile/perdita netta:
$375.65M
Rapporto P/E:
8.7056
EPS:
2.1963
Flusso di cassa netto:
$113.59M
1 W Prestazione:
-3.34%
1M Prestazione:
-30.57%
6M Prestazione:
-10.02%
1 anno Prestazione:
-7.27%
Intervallo 1D:
$18.87
$19.76
Intervallo di 1 settimana:
$18.39
$19.88
Portata 52W:
$18.39
$30.96
Acadia Pharmaceuticals Inc Stock (ACAD) Company Profile
Nome
Acadia Pharmaceuticals Inc
Settore
Industria
Telefono
858-558-2871
Indirizzo
12830 EL CAMINO REAL, SAN DIEGO
Compare ACAD vs VRTX, MRNA, REGN, ARGX, ONC
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
ACAD
Acadia Pharmaceuticals Inc
|
19.12 | 3.29B | 1.10B | 375.65M | 113.59M | 2.1963 |
VRTX
Vertex Pharmaceuticals Inc
|
499.74 | 126.66B | 12.34B | 4.34B | 3.71B | 16.87 |
MRNA
Moderna Inc
|
218.01 | 87.04B | 2.23B | -3.19B | -1.60B | -8.1462 |
REGN
Regeneron Pharmaceuticals Inc
|
790.74 | 81.41B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
819.14 | 51.51B | 4.16B | 1.29B | 734.26M | 19.58 |
ONC
Beone Medicines Ltd Adr
|
369.06 | 41.75B | 5.76B | 514.49M | 1.10B | 4.4813 |
Acadia Pharmaceuticals Inc Stock (ACAD) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-10-13 | Downgrade | UBS | Buy → Neutral |
| 2026-03-25 | Aggiornamento | BofA Securities | Neutral → Buy |
| 2026-02-24 | Iniziato | Wolfe Research | Outperform |
| 2026-02-23 | Aggiornamento | Mizuho | Neutral → Outperform |
| 2025-10-21 | Iniziato | Citigroup | Buy |
| 2025-05-21 | Aggiornamento | Deutsche Bank | Hold → Buy |
| 2025-02-11 | Iniziato | Deutsche Bank | Hold |
| 2025-01-03 | Downgrade | Guggenheim | Buy → Neutral |
| 2024-10-10 | Ripresa | Raymond James | Mkt Perform |
| 2024-08-07 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2024-06-27 | Iniziato | BMO Capital Markets | Outperform |
| 2024-03-12 | Downgrade | Mizuho | Buy → Neutral |
| 2024-03-12 | Reiterato | Needham | Buy |
| 2024-01-30 | Iniziato | Robert W. Baird | Outperform |
| 2024-01-24 | Aggiornamento | Needham | Hold → Buy |
| 2023-12-19 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2023-12-14 | Downgrade | Deutsche Bank | Buy → Hold |
| 2023-12-13 | Iniziato | Citigroup | Buy |
| 2023-12-12 | Iniziato | Deutsche Bank | Buy |
| 2023-11-06 | Aggiornamento | Mizuho | Neutral → Buy |
| 2023-10-17 | Iniziato | UBS | Buy |
| 2023-10-10 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2023-01-03 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2022-11-04 | Downgrade | Goldman | Neutral → Sell |
| 2022-11-01 | Iniziato | Loop Capital | Hold |
| 2022-08-08 | Downgrade | Citigroup | Buy → Neutral |
| 2022-08-05 | Downgrade | Citigroup | Buy → Neutral |
| 2022-06-21 | Downgrade | Jefferies | Buy → Underperform |
| 2022-06-16 | Aggiornamento | Jefferies | Hold → Buy |
| 2022-03-16 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2022-02-09 | Aggiornamento | H.C. Wainwright | Neutral → Buy |
| 2022-01-05 | Aggiornamento | Citigroup | Neutral → Buy |
| 2021-12-21 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-11-01 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2021-10-14 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| 2021-09-23 | Ripresa | Needham | Hold |
| 2021-06-10 | Iniziato | Berenberg | Hold |
| 2021-04-07 | Downgrade | H.C. Wainwright | Buy → Neutral |
| 2021-04-06 | Downgrade | Canaccord Genuity | Buy → Hold |
| 2021-04-06 | Downgrade | Goldman | Buy → Neutral |
| 2021-04-06 | Downgrade | Jefferies | Buy → Hold |
| 2021-04-06 | Downgrade | Mizuho | Buy → Neutral |
| 2021-04-05 | Downgrade | Raymond James | Outperform → Mkt Perform |
| 2021-03-10 | Downgrade | BofA Securities | Buy → Neutral |
| 2021-03-09 | Downgrade | Citigroup | Buy → Neutral |
| 2021-03-09 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-03-09 | Reiterato | H.C. Wainwright | Buy |
| 2021-03-09 | Downgrade | Raymond James | Strong Buy → Outperform |
| 2021-03-09 | Downgrade | Stifel | Buy → Hold |
| 2020-12-16 | Iniziato | Mizuho | Buy |
| 2020-11-16 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2020-08-25 | Iniziato | Raymond James | Outperform |
| 2020-08-20 | Iniziato | Morgan Stanley | Overweight |
| 2020-07-07 | Aggiornamento | Stifel | Hold → Buy |
| 2020-04-16 | Iniziato | Jefferies | Buy |
| 2020-03-31 | Aggiornamento | Goldman | Neutral → Buy |
| 2020-03-06 | Iniziato | Citigroup | Buy |
| 2019-12-16 | Iniziato | Guggenheim | Buy |
| 2019-10-24 | Iniziato | Oppenheimer | Perform |
| 2019-10-01 | Iniziato | RBC Capital Mkts | Outperform |
| 2019-09-13 | Aggiornamento | SVB Leerink | Mkt Perform → Outperform |
| 2019-09-10 | Aggiornamento | Canaccord Genuity | Hold → Buy |
| 2019-07-23 | Reiterato | Needham | Buy |
| 2018-12-10 | Iniziato | Canaccord Genuity | Hold |
| 2018-09-21 | Aggiornamento | Piper Jaffray | Neutral → Overweight |
| 2018-08-09 | Reiterato | Stifel | Hold |
| 2018-08-07 | Iniziato | Stifel | Hold |
| 2018-08-06 | Downgrade | Piper Jaffray | Overweight → Neutral |
| 2017-10-06 | Ripresa | Goldman | Neutral |
Mostra tutto
Acadia Pharmaceuticals Inc Borsa (ACAD) Ultime notizie
Press Release Distribution & Media Outreach Platform for PR Agencies - ACCESS Newswire
UBS cuts target for ACADIA Pharmaceuticals stock to USD 23.00 - ad-hoc-news.de
ACADIA Pharmaceuticals Inc. (ACAD) Stock Forecasts - Yahoo Finance
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc.ACAD - PR Newswire
ACADIA Pharmaceuticals Inc. (ACAD) Stock Forecasts - Yahoo! Finance Canada
ACADIA Pharmaceuticals Inc. (ACAD) Stock forecasts - Yahoo Finance UK
Law firm probes ACADIA investors' claims after trial misses key endpoint, stock drops sharply. - Pluang
Acadia Pharmaceuticals stock hits 52-week low at 19.01 USD - Investing.com
Can Nuplazid and Daybue Strengthen Acadia's Growth Prospects? - Zacks Investment Research
UBS Downgrades ACADIA Pharmaceuticals to Neutral From Buy, $23 Price Target - Yahoo Finance
4 CNS Drug Stocks Worth Watching This World Mental Health Day - Zacks Investment Research
RBC Trims Price Target on ACADIA Pharmaceuticals to $36 From $37, Keeps Outperform Rating - Yahoo Finance
ACADIA Pharmaceuticals Inc. (ACAD) Stock Forecasts - Yahoo Finance
RBC keeps Outperform on ACADIA Pharmaceuticals stock at USD 37 - AD HOC NEWS
RBC reiterates Outperform on ACADIA Pharmaceuticals stock - AD HOC NEWS
Acadia Pharmaceuticals (ACAD) Secures Patent And Phase 2 Progress, Is It 38% Below Fair Value? - Yahoo Finance
Acadia Pharmaceuticals (ACAD) Resolves Nuplazid Patent Dispute, Boosting Market Outlook - GuruFocus
RBC Capital reiterates Acadia Pharmaceuticals stock rating on patent developments - Investing.com
Acadia Pharmaceuticals (ACAD) and Zydus Move to Dismiss Patent L - GuruFocus
ACADIA Pharmaceuticals Inc. (0A4W.IL) Stock Price, News, Quote & History - Yahoo! Finance Canada
ACADIA Pharmaceuticals Inc. (ACAD) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
ACADIA Pharmaceuticals Inc. (ACAD) Stock forecasts - Yahoo Finance Australia
Acadia Pharmaceuticals stock hits 52-week low at $19.66 - Investing.com
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of ACADIA Pharmaceuticals Inc.ACAD - PR Newswire
ACADIA Pharmaceuticals Inc. (ACAD) Stock Forecasts - Yahoo Finance
Acadia's Daybue Patent Allowance Extends U.S. Protection to March 2041 - Zacks Investment Research
Acadia's Daybue Patent Allowance Extends U.S. Protection to March 2041 - Yahoo Finance
Acadia debuts 63,000 sq. ft. Princeton office, biopharma hub designed by Ware Malcomb - Real Estate NJ
Acadia Pharmaceuticals Announces Allowance of U.S. Patent Covering Weight-Banded Dosing of Trofinetide, extending U.S. patent protections to March 2041 - biospace.com
Acadia Pharmaceuticals (ACAD) Secures USPTO Notice of Allowance for Rett Syndrome Patent - GuruFocus
Acadia Pharmaceuticals Gets US Patent Office Allowance for Trofinetide Dosing Patent - Yahoo Finance
Acadia Pharmaceuticals Announces Allowance of U.S. Patent Covering Weight-Banded Dosing of Trofinetide, extending U.S. patent protections to March 2041 - Yahoo Finance
Acadia Pharmaceuticals (ACAD) Stock Trades At A Discount After A 29% Drop - Yahoo Finance
Acadia Pharmaceuticals (ACAD) Stock May Be Mispriced After Mixed Phase III Push - simplywall.st
Acadia Pharmaceuticals (ACAD) Shares Drop After Phase 2 RADIANT Study Results - GuruFocus
Acadia Pharmaceuticals drops 7%, continuing fall after drug trial results (ACAD:NASDAQ) - Seeking Alpha
Acadia Pharmaceuticals' Risk-Reward Favorable After Remlifanserin Data, Deutsche Bank Says - Yahoo Finance
Ware Malcomb says construction finished on Acadia Pharmaceuticals’ Princeton office - ROI-NJ
Acadia Pharmaceuticals Fell 19% Today. Here’s Where the Stock Could Go in 2026 - Yahoo Finance
Biotech Rattled On Surprise Setback For Alzheimer's Drug - Investor's Business Daily
ACADIA Pharmaceuticals (ACAD) Drops 8.6% to $23.25 - AlphaStreet
Why Is Acadia Pharmaceuticals Stock Tumbling Today?ACADIA Pharmaceuticals (NASDAQ:ACAD) - benzinga.com
Acadia Pharmaceuticals: Remlifanserin Is In Trouble (NASDAQ:ACAD) - Seeking Alpha
Acadia Pharmaceuticals shares slide on mixed Alzheimer's psychosis data - Yahoo Finance
Acadia slides on Phase 2 miss in Alzheimer’s psychosis but keeps moving asset forward - biospace.com
Acadia Pharmaceuticals Shares Fall After RADIANT Phase 2 Study Misses Primary Endpoint - Yahoo Finance
ACADIA Pharmaceuticals' Shares Drop 10% Pre-Bell After Remlifanserin Study Misses Main Endpoint - Yahoo Finance
Acadia Pharmaceuticals Announces Phase 3 Enabling Topline Results from Phase 2 RADIANT Study of Remlifanserin for the Treatment of Alzheimer’s Disease Psychosis (ADP) - Yahoo Finance
ACADIA Pharmaceuticals Inc. (ACAD) Discusses Top-Line Phase II Results From RADIANT Study of Remlifanserin in Alzheimer's Disease PsychosisSlideshow (NASDAQ:ACAD) 2026-09-24 - Seeking Alpha
ACADIA Pharmaceuticals (ACAD) Gets ‘Sell’ Rating on Weak Trial Results, Shares Fall 13% - Yahoo Finance
Acadia Pharmaceuticals Inc Azioni (ACAD) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Acadia Pharmaceuticals Inc Azioni (ACAD) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER |
Aug 06 '26 |
Sale |
29.22 |
14,292 |
417,604 |
67,828 |
| Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER |
Aug 05 '26 |
Option Exercise |
17.84 |
5,849 |
104,346 |
73,677 |
| Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER |
Aug 05 '26 |
Sale |
29.00 |
5,849 |
169,638 |
67,828 |
| Schneyer Mark C. | Officer |
Aug 05 '26 |
Proposed Sale |
27.15 |
5,849 |
158,800 |
0 |
| Thompson Elizabeth H.Z. | EVP, Head of Research & Dev |
Jul 30 '26 |
Sale |
26.13 |
16,558 |
432,663 |
18,994 |
| Kihara James | Officer |
Jun 26 '26 |
Proposed Sale |
26.00 |
11,421 |
297,000 |
0 |
| JAMES K KIHARA | Officer |
May 26 '26 |
Proposed Sale |
21.18 |
5,401 |
114,394 |
0 |
| Kihara James | PRINCIPAL ACCOUNTING OFFICER |
May 26 '26 |
Sale |
21.18 |
5,401 |
114,393 |
24,509 |
| Kihara James | PRINCIPAL ACCOUNTING OFFICER |
May 04 '26 |
Sale |
21.79 |
1,332 |
29,024 |
29,129 |
| Schneyer Mark C. | EVP, CHIEF FINANCIAL OFFICER |
May 04 '26 |
Sale |
21.79 |
3,506 |
76,396 |
66,145 |
2.45%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):